BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 536 filers reported holding BIO-TECHNE CORP in Q1 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,693,309 | -58.0% | 24,876 | -49.6% | 0.01% | -57.9% |
| Q2 2023 | $4,027,869 | -87.9% | 49,343 | -89.0% | 0.02% | -88.5% |
| Q1 2023 | $33,241,794 | +99.6% | 448,063 | +123.0% | 0.16% | +77.4% |
| Q4 2022 | $16,652,498 | -21.8% | 200,923 | +168.1% | 0.09% | -19.1% |
| Q3 2022 | $21,287,000 | +27.0% | 74,955 | +55.0% | 0.12% | +32.2% |
| Q2 2022 | $16,761,000 | +1077.0% | 48,352 | +1370.6% | 0.09% | +987.5% |
| Q1 2022 | $1,424,000 | -76.4% | 3,288 | -71.8% | 0.01% | -75.8% |
| Q4 2021 | $6,023,000 | +326.0% | 11,642 | +299.0% | 0.03% | +266.7% |
| Q3 2021 | $1,414,000 | +583.1% | 2,918 | +535.7% | 0.01% | +800.0% |
| Q2 2021 | $207,000 | -96.3% | 459 | -97.4% | 0.00% | -97.9% |
| Q4 2020 | $5,634,000 | +22.5% | 17,743 | -4.4% | 0.05% | +23.7% |
| Q3 2020 | $4,600,000 | +166.0% | 18,569 | +183.6% | 0.04% | +90.0% |
| Q2 2020 | $1,729,000 | -66.2% | 6,548 | -75.7% | 0.02% | -86.4% |
| Q1 2020 | $5,109,000 | -38.3% | 26,942 | -28.6% | 0.15% | -8.7% |
| Q4 2019 | $8,282,000 | +78.5% | 37,731 | +59.1% | 0.16% | +98.8% |
| Q3 2019 | $4,641,000 | -1.1% | 23,717 | +5.4% | 0.08% | -37.7% |
| Q2 2019 | $4,691,000 | +348.0% | 22,502 | +326.9% | 0.13% | +306.2% |
| Q1 2019 | $1,047,000 | – | 5,271 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ROWLANDMILLER & PARTNERS.ADV | 47,975 | $3,701,751 | 0.85% |
| Diversified Trust Co | 13,882 | $1,071,135 | 0.04% |
| Czech National Bank | 27,698 | $2,137,178 | 0.03% |
| FULTON BANK, N.A. | 5,444 | $420,058 | 0.02% |
| DnB Asset Management AS | 27,637 | $2,132,471 | 0.01% |
| Versant Capital Management, Inc | 36 | $2,778 | 0.00% |
| MASSMUTUAL TRUST CO FSB/ADV | 371 | $28,626 | 0.00% |
| Bartlett & Co. LLC | 172 | $13 | 0.00% |